Compare BLMN & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLMN | QDEL |
|---|---|---|
| Founded | 1988 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 905.9M | 989.5M |
| IPO Year | 2012 | 2022 |
| Metric | BLMN | QDEL |
|---|---|---|
| Price | $8.62 | $11.93 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 8 | 4 |
| Target Price | $7.88 | ★ $28.25 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.99% | N/A |
| EPS Growth | ★ 106.71 | 45.35 |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $4,213,346,000.00 | $2,730,200,000.00 |
| Revenue This Year | $2.07 | $3.51 |
| Revenue Next Year | $1.81 | $3.86 |
| P/E Ratio | $8.95 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.19 | $9.92 |
| 52 Week High | $12.63 | $35.58 |
| Indicator | BLMN | QDEL |
|---|---|---|
| Relative Strength Index (RSI) | 35.14 | 33.35 |
| Support Level | $7.33 | $11.37 |
| Resistance Level | $9.28 | $12.85 |
| Average True Range (ATR) | 0.55 | 0.75 |
| MACD | -0.29 | -0.18 |
| Stochastic Oscillator | 2.54 | 5.63 |
Bloomin Brands Inc is a casual dining restaurant company, with a portfolio of, differentiated restaurant concepts. Its restaurant portfolio includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill and Fleming's Prime Steakhouse & Wine Bar. Its restaurant concepts range in price point and degree of formality from casual (Outback Steakhouse and Carrabba's Italian Grill) to polished casual (Bonefish Grill) and fine dining (Fleming's Prime Steakhouse & Wine Bar). The U.S. segment includes all restaurants operating in the U.S. while franchised restaurants operating outside the U.S. are included in the international franchise segment.
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.